Global Next Generation Immunotherapies Market - 2023-2030

Global Next Generation Immunotherapies Market - 2023-2030

Global next generation immunotherapies market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.

The global next generation immunotherapies market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. Years of oncology clinical experience have shown that cancer immunotherapy offers unheard-of therapeutic advantages. Tragically, only a small percentage of patients benefit from immunotherapies today. Recently, RNA lipid nanoparticles have become versatile instruments for immune activation.

Government partnerships, investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like monoclonal antibodies or immune checkpoint inhibitors and boost the global next generation immunotherapies market. The respective innovative immunotherapies are being developed by several researchers and currently are being studied.

Market Dynamics: Drivers & Restraints

Growing collaborations and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for next generation immunotherapies owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On November 17, 2022, in order to develop conditionally-activated investigational bispecific cancer therapies using CytomX's Probody helpful platform and Regeneron's Veloci-Bi bispecific antibody development platform, CytomX Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. collaborated and agreed to a licensing agreement. Strategically, the team aims to create exploratory Regeneron bispecifics that are dormant until activated by proteases in the microenvironment of tumors by utilizing CytomX's biologic masking techniques.

Additionally, on June 2, 2022, Immatics N.V. and Bristol Myers Squibb have broadened their strategic partnership to explore the development of numerous allogeneic standard TCR-T and/or CAR-T products. Immatics N.V. is a clinical-stage biopharmaceutical business engaged in the discovery and creation of T cell-redirecting cancer immunotherapies.

Furthermore, the rising utilization of novel technology and product launches for the several research purposes. Rising oncology cases and increasing research for innovative treatment product development will be a major factor driving the growth of the next generation immunotherapies market.

Side effects associated with the immunotherapy

The immune system may assault healthy cells as a side effect of immunotherapy. ""Immune-related adverse effects,"" sometimes known as side effects, may result from this. These could occur at any point over the course of the therapy or occasionally even after finishing immunotherapy. Immunotherapy comes with a variety of adverse effects. Immune cells as well as healthy bodily tissues are frequently attacked by immune cells as immune checkpoint inhibitor side effects. This process is known as inflammation.

A typical side effect of CAR T-cell treatment is infection. They frequently occur immediately after the infusion because the immune system's ability to combat infections may be compromised. Fever, nausea, exhaustion, headaches, weakness, and an overall sensation of discomfort are all signs of infection.

Segment Analysis

The global next generation immunotherapies market is segmented based on immunotherapy type, route of administration, distribution channel and region.

Monoclonal Antibodies segment accounted for approximately 32% of market share

Immune system proteins known as monoclonal antibodies are produced in a laboratory. The body naturally produces antibodies, which assist the immune system in identifying pathogenic microorganisms like bacteria and viruses and marking them for eradication. Cancer treatment frequently makes use of monoclonal antibodies.

As a form of targeted cancer therapy, they are created to interact with particular targets. Certain monoclonal antibodies are also used in immunotherapy because they assist the body fight cancer by activating the immune system. As an illustration, certain monoclonal antibodies label cancer cells to help the immune system more easily identify and eliminate them.

On December 21, 2022, the U.S. Food and Drug Administration (FDA) has approved Genentech's Actemra (tocilizumab) intravenous (IV) for the management of COVID-19 in being treated adult patients who receive systemic corticosteroids and need additional oxygen, non-invasive and invasive mechanical ventilation, or oxygenation through extracorporeal membranes (ECMO). Actemra, the first monoclonal antibody approved by the FDA to treat COVID-19, is advised for use as a single, 60-minute IV infusion.

Geographical Penetration

North America accounted for around 38% of market share in 2022

Due to the rising need for next generation immunotherapies in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for next generation immunotherapies.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different types of medicines, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of next generation immunotherapies market share of this region. The market in this area is growing as people become more aware of various novel approved therapies. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global next generation immunotherapies market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for next generation immunotherapies in the U.S. United States have been proactive in executing several initiatives or researches, stimulating next generation immunotherapies demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global next generation immunotherapies market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various therapies, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for next generation immunotherapies. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global next generation immunotherapies market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative immunotherapy type.

Key Developments
• On September 11, 2023, The U.S. Food and Drug Administration (FDA) has authorized the supplemental biologics license application for people 12 years of age and older and granted emergency use authorization for people 6 months to 11 years of age for the companies' monovalent COVID-19 vaccine modified for Omicron XBB.1.5. This was announced by Pfizer Inc. and BioNTech SE.
• On January 9, 2023, in order to find and develop next-generation cancer medicines that will significantly address unmet patient needs, 3T Biosciences and Boehringer Ingelheim have engaged into an strategic partnership and licensing agreement. Boehringer Ingelheim's two-pronged investigation approach combining cancer cell-directed and immune cell-targeting compounds will be combined with 3T Biosciences' unparalleled 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform, further strengthening the company's pipeline.
• On June 4, 2021, in order to develop novel cell-based therapeutics using natural killer (""NK"") cells generated from induced pluripotent stem cells (""iPSCs""), Sorrento Therapeutics, Inc. has entered into another collaborative agreement with research groups affiliated with the NextGenNK Competence Center at the Department of Medicine, Huddinge, Karolinska Institutet in Stockholm, Sweden. The Competence Center for the creation of next-generation cancer immunotherapies based on NK cell (referred to as ""NextGenNK"") is a partnership between Sorrento and KI.

Competitive Landscape

The major global players in the market include Regeneron Pharmaceuticals Inc., AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, MacroGenics, Inc., Mereo Biopharma Group PLC, Sorrento Therapeutics and BioNTech SE.

Why Purchase the Report?
• To visualize the global next generation immunotherapies market segmentation based on immunotherapy type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of next generation immunotherapies market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global next generation immunotherapies market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies